RSS   Newsletter   Contact   Advertise with us
Post Online Media

Atara Biotherapeutics appoints Kanya Rajangam as CMO

Atara BiotherapeuticsAugust 23, 2017, San Francisco, Ca., USA - Atara Biotherapeutics, an "off-the-shelf" T-cell immunotherapy company, announced the appointment of Kanya Rajangam as senior vice president and chief medical officer.
Dr. Rajangam joins Atara from Cleave Biosciences where she served as Chief Medical Officer, overseeing clinical development programs in hematologic and solid tumor malignancies.

Previously, Dr. Rajangam was a Senior Medical Director at Onyx Pharmaceuticals, where she played a key role in the successful FDA and EMA submissions of the multiple myeloma product KYPROLIS (carfilzomib).

Prior to this, Dr. Rajangam was Associate Medical Director at Exelixis, where she designed early-stage oncology clinical studies, including for COMETRIQ (cabozantinib) and COTELLIC (cobimetinib).

Throughout her career, Dr. Rajangam has worked closely with pharmaceutical partners including Amgen, Sanofi, Bristol-Myers Squibb and Genentech to advance oncology programs in all phases of clinical development.

After earning her medical degree from St. John’s Medical College in Bangalore, India, she completed a surgical residency, including a master’s thesis in renal transplantation, at the Postgraduate Institute of Medical Education and Research (India).

Dr. Rajangam then earned her doctorate in biomedical tissue engineering from Northwestern University.




POST Online Media does not use cookies to collect information about visitors.   OK, hide this message   Third party ads may be using cookies, you can see how here.